Non-commercial trials
Trial Study description Status
SENTIX/
ENGOT-cx2/CEEGOG
documents available here
Sentinel node in cervix cancer
A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer
The target size of the SLN Study group: 600 patients
The target size of the Control group: 100 patients
Estimated enrollment period: 2016 – 2020
Ongoing
HE4-FU-OVCA
documents available here
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer
A prospective multicentre observational study
The target size of the group: 150 patients
Collaborative opportunities: the opportunity to join the study is still available (for more information, you are welcome to contact the CEEGOG office)
Ongoing
FERTISS
documents available here
FERTIlity Sparing Surgery in cervical cancer patients outside controlled trials Ongoing
RSS-EAC-PAT
documents available here
The Risk Stratification System for endocervical adenocarcinoma based on tumor pattern and its clinical outcomes  Ongoing
ATALANTE/
ENGOT-ov29/GINECO
A randomized, double blinded, phase III study of Atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and Bevacizumab
The target size of the group: 600 patients
Ongoing
EXPRESSIONVI/
ENGOT-ov40/NOGGO S13
Caroline meets HANNA – Holistic Analysis of longterm survivors with ovarian cancer
The target size of the group: 100-200 per participating country
Ongoing
SIENDO/
BGOG-EN5/ENGOT-EN5
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer.
The target size of the group: 192 patients
Prepared
MARUC/
ENGOT-CX7/NSGO

A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer
The target size of the group: 162 patients
Prepared
ENGOT-EN2-DGCG/
EORTC 55102
A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer
The target size of the group: 240 patients
Enrollment closed
ABRAX/
ENGOT-cx3/CEEGOG
documents available here
Oncological outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of LN positivity Closed
SALVAGE A retrospective trial on patients who have undergone salvage surgery for a recurrent uterine or cervical cancer
Salvage database – data from 620 patients collected, currently results analysed
Closed

 

 

Commercial trials
Trial Study description Status
MK-7339-001-00/
ENGOT-ov43/BGOG
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or
Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-
Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
The target size of the group: 1086 patients
Ongoing
INNOVATE-3/
ENGOT-ov50/BGOG
Pivotal, randomized, open-label
study of Tumor Treating Fields (TTFields, 200kHz) concomitant
with weekly paclitaxel for the treatment of platinum-resistant
ovarian cancer (PROC)
The target size of the group: 540 patients
Ongoing
FIRST
ENGOT-ov44/GINECO
A Patient‑centric, Randomized, Phase 3 comparison of Platinum‑based Therapy with or without bevacizumab to the same plus TSR‑042 as first‑line treatment of stage iii or iv non-mucinous ovarian cancer followed by maintenaNce therapy
The target size of the group: 720 - 960 patients
Ongoing
ATHENA/
ENGOT-ov45/NCRI
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
The target size of the group: 1000 patients
Prepared
SOV09/VITALIA/
ENGOT-ov53/CEEGOG
A phase III, multicentre, randomized, double-blind, placebo-controlled trial of DCVAC/OvCa added to standard of care induction and maintenance therapy in patients with relapsed platinum-sensitive ovarian, fallopian tube, and primary peritoneal carcinoma
The target size of the group: 678 patients
Prepared
GCT1015-05/
BGOG/ENGOT-cx8
A Phase 2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer
The target size of the group: 140 patients
Prepared
GCT1015-07/
BGOG/ENGOT-cx12
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer
The target size of the group: 486 patients
Prepared
FERMATA/
ENGOTcx13/AGO
An International Randomized Double-blind Clinical Trial of BCD-100
Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer
The target size of the group: 316 patients
Prepared
RUBY/
ENGOT EN-6/NSGO

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus
Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)
The target size of the group: 470 patients
Prepared
SOTIO/
SOV01
SOV01 A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma
The target size of the group: additional 30 patients
Enrollment closed
SOTIO/
SOV06
SOV06 An open-label, single-group, multicenter phase II clinical trial evaluating the effect of maintenance DCVAC/OvCa after standard of care therapy in women with first relapse of platinum-sensitive epithelial ovarian carcinoma
The target size of the group: 30 patients
Enrollment closed
IMAGYN050/
YO39523/GOG-3015/ENGOT-ov3
A phase III, multicenter, randomized study of Atezolizumab versus placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
The target size of the group: 1300 patients
Enrollment closed
PRIMA/
ENGOT-ov26/GEICO/1509
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Studyof Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
The target size of the group: 620 patients
Enrollment closed
GCT1015-04/
BGOG/ENGOT-cx6
A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®‑TF‑ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer
The target size of the group: 100 patients
Enrollment closed
JAVELIN OVARIAN 200 A phase 3, multicenter, randomized, open-label study of Avelumab (MSB0010718C) alone or in combination with Pegylated liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer
Approximately 550 patients will be randomized
Enrollment closed
SOTIO/
SOV02
SOV02 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with relapsed platinum sensitive epithelial ovarian carcinoma Enrollment closed
SOTIO/
SOV03
SOV03 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy in women with relapsed platinum resistant epithelial ovarian carcinoma Closed
MILO/
ENGOT-ov11
MEK Inhibitor in Low-grade Serous Ovarian Cancer
A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Closed
NOVA/
ENGOT-ov16
Niraparib in OVArian cancer
A randomized, double-blind phase 3 trial of maintenance with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer
Closed